Indian merger expands pharmaceutical analysis capabilities

The GBA Group is further expanding its presence in India’s fast-growing life sciences sector through a strategic merger between its Indian subsidiary, Eureka Analytical Services Pvt Ltd, and Teena Biolabs Pvt Ltd, a respected provider of pharmaceutical analytics. The move will significantly strengthen GBA’s position in the region by uniting the expertise, infrastructure, and regulatory standing of both companies.

Established in 1999, Teena Biolabs has developed a strong reputation in India for method development, validation, and routine batch testing. With a team of 200 employees across its Hyderabad headquarters and a second site in Panchkula, Teena serves both domestic pharmaceutical clients and exporters to regulated markets including the United States and Europe. Its Hyderabad laboratory holds US-FDA inspected status, giving it a key advantage in serving international pharmaceutical supply chains.

By acquiring a majority stake in Teena, Eureka will operate two US-FDA approved facilities in India, offering a robust and compliant platform for pharmaceutical analysis. This enhanced footprint supports Eureka’s strategic goal of becoming a top-tier analytical services provider in the Indian market, while also extending GBA Group’s international laboratory network.

“India is one of the most dynamic pharmaceutical markets globally,” said Steffen Walter, CEO of the GBA Group. “This merger strengthens our service offering, bringing together Eureka’s and Teena’s complementary capabilities to better support both local and global clients.”

Eureka’s founders, Dr Gouri Satpathy and Sanjeev Khatri, described the deal as a ‘major milestone’ in expanding their pharmaceutical service portfolio. “The merger allows us to serve the Indian pharmaceutical sector more holistically and establish Eureka and GBA Group as a leading name in laboratory analysis,” they said.

Teena’s founders, Anjaiah and Nirooparani Katike, added that joining forces with a global organisation that already has a strong Indian base opens up new growth opportunities. “Our clients will benefit from a wider service offering and the reach of an international network,” they said.

The partnership is expected to support the growing demand for high-quality laboratory services in India, while helping international pharma companies navigate regulatory requirements and accelerate development timelines.

More information online